Research analysts at Lake Street Capital assumed coverage on shares of AbCellera Biologics (NASDAQ:ABCL – Get Free Report) in a report released on Wednesday, Briefing.com reports. The brokerage set a “buy” rating and a $19.00 price target on the stock. Lake Street Capital‘s price objective would indicate a potential upside of 72.26% from the stock’s previous close.
Other research analysts have also issued research reports about the company. Piper Sandler raised their price objective on AbCellera Biologics from $12.00 to $20.00 and gave the company an “overweight” rating in a research report on Monday. The Goldman Sachs Group initiated coverage on AbCellera Biologics in a report on Thursday, September 24th. They issued a “neutral” rating and a $13.00 target price on the stock. Truist Financial boosted their target price on AbCellera Biologics from $12.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, August 11th. Stifel Nicolaus increased their price target on AbCellera Biologics from $9.00 to $14.00 and gave the company a “buy” rating in a research note on Tuesday, November 10th. Finally, Wall Street Zen upgraded AbCellera Biologics from a “sell” rating to a “hold” rating in a report on Saturday, October 31st. Two analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, AbCellera Biologics presently has an average rating of “Moderate Buy” and an average target price of $16.75.
View Our Latest Analysis on AbCellera Biologics
AbCellera Biologics Stock Performance
Shares of NASDAQ:ABCL opened at $11.03 on Wednesday. The firm has a market cap of $3.60 billion, a price-to-earnings ratio of -22.98 and a beta of 1.59. The firm has a fifty day moving average price of $12.32 and a 200 day moving average price of $7.30. AbCellera Biologics has a fifty-two week low of $2.74 and a fifty-two week high of $15.02.
AbCellera Biologics (NASDAQ:ABCL – Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.04. The company had revenue of $10.64 million for the quarter, compared to the consensus estimate of $8.42 million. AbCellera Biologics had a negative net margin of 218.54% and a negative return on equity of 15.35%. During the same period in the previous year, the firm posted ($0.19) EPS. As a group, research analysts predict that AbCellera Biologics will post -0.65 earnings per share for the current year.
Insider Transactions at AbCellera Biologics
In other AbCellera Biologics news, major shareholder Holdings Ltd. Thermopylae purchased 60,565 shares of the firm’s stock in a transaction that occurred on Thursday, November 12th. The shares were bought at an average price of $11.54 per share, with a total value of $698,920.10. Following the completion of the purchase, the insider directly owned 56,194,662 shares in the company, valued at $648,486,399.48. This trade represents a 0.11% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 28.40% of the stock is currently owned by insiders.
Institutional Trading of AbCellera Biologics
Large investors have recently made changes to their positions in the business. Marshall Wace LLP raised its position in shares of AbCellera Biologics by 370.9% during the 3rd quarter. Marshall Wace LLP now owns 8,958,273 shares of the company’s stock valued at $130,701,000 after buying an additional 7,056,082 shares in the last quarter. Bank of America Corp DE bought a new position in shares of AbCellera Biologics in the 2nd quarter valued at about $48,211,000. BlackRock Inc. purchased a new position in AbCellera Biologics in the second quarter worth about $29,872,000. Goldman Sachs Group Inc. grew its position in AbCellera Biologics by 256.2% in the third quarter. Goldman Sachs Group Inc. now owns 837,416 shares of the company’s stock worth $12,218,000 after acquiring an additional 602,289 shares in the last quarter. Finally, Great Point Partners LLC purchased a new position in AbCellera Biologics in the third quarter worth about $8,754,000. 61.42% of the stock is currently owned by institutional investors.
AbCellera Biologics Company Profile
AbCellera Biologics Inc. is a biotechnology company headquartered in Vancouver, Canada. It discovers and develops antibody-based medicines, using laboratory and computational tools to identify and optimize antibodies that may be developed into treatments for disease. The company works with pharmaceutical and biotechnology partners on antibody discovery and drug development, while also advancing a portfolio of its own therapeutic candidates. Its work spans early-stage research through preclinical and clinical development, with programs focused on areas including cancer and immune-related diseases.
Further Reading
- Five stocks we like better than AbCellera Biologics
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
Receive News & Ratings for AbCellera Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbCellera Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
